Danshensu
Based on 8 publication(s) in Google Scholar
Danshensu (Dan shen suan A), an orally active phenolic compound, can induce Nrf2/HO-1 activation and inhibition of NF-κB pathway. Danshensu reduces reactive oxygen species (ROS) production, upregulates antioxidant defense mechanism and inhibits intrinsic apoptotic pathway. Danshensu displays a potent antiviral activity against SARS-CoV-2 with EC50 of 0.97 μM. Danshensu has anti-oxidation, anti-apoptosis, anti-lung inflammatory and has the potential for COVID-19, cardiovascular and cerebrovascular diseases research.
For research use only. We do not sell to patients.
- Purity: 99.90%
- CAS No.: 76822-21-4
- Formula: C9H10O5
- Molecular Weight:198.17
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Anti-Infection Compound Library
HY-L002
-
Apoptosis Compound Library
HY-L003
-
Immunology/Inflammation Compound Library
HY-L007
-
Metabolism/Protease Compound Library
HY-L012
-
NF-κB Signaling Compound Library
HY-L014
-
Stem Cell Signaling Compound Library
HY-L017
-
Natural Product Library
HY-L021
-
Anti-Cancer Compound Library
HY-L025
-
Antiviral Compound Library
HY-L027
-
Anti-Aging Compound Library
HY-L034
-
Antioxidant Compound Library
HY-L037
-
Differentiation Inducing Compound Library
HY-L038
-
Oxygen Sensing Compound Library
HY-L045
-
Anti-Cardiovascular Disease Compound Library
HY-L046
-
Ferroptosis Compound Library
HY-L051
-
Medicine Food Homology Compound Library
HY-L055
-
Phenols Library
HY-L057
-
Pyroptosis Compound Library
HY-L059
-
Orally Active Compound Library
HY-L061
-
Traditional Chinese Medicine Active Compound Library
HY-L065
-
FDA Approved & Pharmacopeial Drug Library
HY-L066
-
Anti-Breast Cancer Compound Library
HY-L074
-
Anti-Pancreatic Cancer Compound Library
HY-L077
-
Anti-Blood Cancer Compound Library
HY-L079
-
Anti-Cancer Metabolism Compound Library
HY-L083
-
Anti-Obesity Compound Library
HY-L087
-
Transcription Factor-Targeted Library
HY-L090
-
Anti-Liver Cancer Compound Library
HY-L101
-
Anti-Cancer Natural Product Library
HY-L107
-
Antidepressant Compound Library
HY-L108
-
Antiviral Traditional Chinese Medicine Active Compound Library
HY-L113
-
Anti-inflammatory Traditional Chinese Medicine Active Compound Library
HY-L114
-
Plant-Sourced Natural Product Library
HY-L115
-
Anti-Prostate Cancer Compound Library
HY-L124
-
Anti-Pulmonary Fibrosis Compound Library
HY-L125
-
Cancer Stem Cells Compound Library
HY-L135
-
Pain-Related Compound Library
HY-L139
-
Cell Death Library
HY-L162
-
Anti-Hematopathy Compound Library
HY-L171
-
Anti-Ovarian Cancer Compound Library
HY-L173
-
Multi-Target Compound Library
HY-L176
-
Radioprotector Library
HY-L178
-
Bioactive Compound Library Max
HY-L181
-
Natural Product Library Plus
HY-L021P
-
Natural Product and Natural Product-Like Compound Library
HY-L021M
-
Bioactive Compound Library
HY-L001
-
Anti-Fibrosis Compound Library
HY-L185
-
PBCRBS Traditional Chinese Medicine Compound Library
HY-L193
-
Heat-Clearing and Detoxification Traditional Chinese Medicine Compound Library
HY-L194
-
Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library
HY-L199
-
RO5 Drug-like Natural Product Library
HY-L200
-
Cell Proliferation Compound Library
HY-L201
-
High-Throughput Bioactive Compound Library
HY-L205
-
High-Throughput Natural Product Library
HY-L206
-
Ancient Chinese Classical Formulas Traditional Chinese Medicine Active Compound Library
HY-L209
-
Diarrhea-Related Traditional Chinese Medicine Active Compound Library
HY-L224
-
Amino Acid Metabolite Compound Library
HY-L227
-
Mongolian Medicine Compound Library
HY-L238
-
Lactylation Compound Library
HY-L249
-
Mass Spectrometry Natural Product Library
HY-L262
-
3D Diverse Fragment Library
HY-L903
Publications Citing Use of MedChemExpress (MCE) Danshensu
More- Phytomedicine. 2025 Feb:137:156378. [Abstract]
- Phytomedicine. 2023 May:113:154743. [Abstract]
- Food Sci Hum Wellness. 2025.
- Cancer Immunol Immunother. 2025 Jun 30;74(8):256. [Abstract]
- Eur J Pharmacol. 2025 Feb 1:177296. [Abstract]
- J Tradit Complement Med. 2025 Feb 7;15(4):434-445. [Abstract]
- Breast Cancer Res Treat. 2024 Dec;208(3):657-671. [Abstract]
- Vet Microbiol. 2026 May:316:110992. [Abstract]
Customer Validation & Images
-
In Vivo Efficacy Study
-
WB
-
IF
-
Histological Imaging/Staining
-
IF
Biological Activity
Danshensu (Dan shen suan A) potently inhibits the entry of SARS-CoV-2 S protein-pseudo-typed virus (SARS-CoV-2 S) into ACE2-overexpressed HEK-293T cells (IC50=0.31 μM) and Vero-E6 cell (IC50=4.97 μM)[1].
Danshensu (0-100 μM; for 24 h) at higher concentrations (50 and 100 μM) causes significant reduction in migration and invasion of both FaDu and Ca9-22 cells[2].
Danshensu (0-100 μM; for 24 h)dose-dependently reduced the phosphorylation of ERK and p38 phosphorylation in FaDu cell[2].
Danshensu (0-100 μM; for 24, 48, 72 h) does not have any cytotoxic effect on human oral cancer cells[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:FaDu and Ca9-22 cells
-
Concentration:25, 50, and 100 μM
-
Incubation Time:24 h
-
Result:At higher concentrations (50 and 100 μM) caused significant reduction in migration and invasion of both FaDu and Ca9-22 cells.
-
Cell Line:FaDu and Ca9-22 cells
-
Concentration:25, 50, and 100 μM
-
Incubation Time:24 h
-
Result:Phosphorylation of ERK reduced dose-dependently after 24 h in FaDu cell.
Caused significant reduction in p38 phosphorylation.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Adult BALB/c mice (male, 6-8 weeks, 20±2 g)[1]
-
Dosage:25, 50, 100 mg/kg
-
Administration:Oral administration (daily for 7 continuous days) or i.v. (once)
-
Result:Could prevent SARS-CoV-2 S protein-induced acute lung inflammation.
Ameliorated inflammatory cytokines in serum and lung tissue.
Chemical Information
-
CAS No. 76822-21-4
-
Appearance Solid
-
Molecular Weight 198.17
-
Formula C9H10O5
-
Color White to gray
-
SMILES
OC1=C(C=CC(C[C@H](C(O)=O)O)=C1)O
-
Synonyms
Dan shen suan A; Salvianic acid A
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (8)
-
Journal Impact Factor
-
Most Recent
-
Phytomedicine
Danshensu enhances autophagy and reduces inflammation by downregulating TNF-α to inhibit the NF-κB signaling pathway in ischemic flaps. [Abstract]2025 Feb:137:156378. PMID: 39818119
Danshensu purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2025 Feb:137:156378. [Abstract]
Danshensu (DSS；40, 60 mg/kg; IP; daily for 7 days) significantly increased the flap survival rate in the C57BL/6J mouse.
Danshensu purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2025 Feb:137:156378. [Abstract]
Danshensu (DSS；40, 60 mg/kg; IP; daily for 7 days) increased the protein expression of Cadherin5, MMP9, and VEGFA in the C57BL/6J mouse. Representative western blot images of Cadherin5, MMP9, and VEGFA in mouse skin tissue lysates, with density quantification and statistical analysis of protein levels in each group.
Danshensu purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2025 Feb:137:156378. [Abstract]
Danshensu (DSS; 40, 60 mg/kg; IP; daily for 7 days) showed the number of blood vessels significantly decreased after ischemic injury of the skin flap. This result was reversed with the use of DSS.
Danshensu purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2025 Feb:137:156378. [Abstract]
Danshensu (DSS; 40, 60 mg/kg; IP; daily for 7 days) increased average vessel density in mouse.
Danshensu purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2025 Feb:137:156378. [Abstract]
Danshensu (DSS; 40, 60 mg/kg; IP; daily for 7 days) showed that the proportion of GSDMD-N and Caspase-1 positive cells was considerably higher following ischemic injury of the skin flap and notably reduced after DSS treatment. Immunofluorescence staining of Caspase-1 (red) on skin tissue sections from each group, with DAPI staining for cell nuclei (blue).
Danshensu purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2025 Feb:137:156378. [Abstract]
Danshensu (DSS; 40, 60 mg/kg; IP; daily for 7 days) decreased the protein expression of GSDMD-N and Caspase-1 in C57BL/6 J mice.
-
Phytomedicine
Anti-inflammatory effect of Danhong injection through inhibition of GSDMD-mediated pyroptosis. [Abstract]2023 May:113:154743. PMID: 36893672 -
-
Cancer Immunol Immunother
Salvianic acid A enhances anti-PD-1 therapy by promoting HEV-mediated stem-like CD8 T cells infiltration in TNBC. [Abstract]2025 Jun 30;74(8):256. PMID: 40586931 -
Eur J Pharmacol
Sodium Danshensu alleviates bone cancer pain by inhibiting the osteoclast differentiation and CGRP expression. [Abstract]2025 Feb 1:177296. PMID: 39900329 -
J Tradit Complement Med
Salvianic acid A promotes osteogenic differentiation of bone marrow mesenchymal stem cells in senile osteoporosis through bromodomain-containing protein 4/Ariadne RBR E3 ubiquitin-protein ligase 1/Rubicon axis. [Abstract]2025 Feb 7;15(4):434-445. PMID: 40677544 -
Breast Cancer Res Treat
Phosphoenolpyruvate carboxykinase-2 (PCK2) is a therapeutic target in triple-negative breast cancer. [Abstract]2024 Dec;208(3):657-671. PMID: 39177932 -
Vet Microbiol
The Chinese medicine monomer Schisandrin C inhibits PRRSV infection by regulating the OGT-PI3K/AKT/mTOR signaling pathway. [Abstract]2026 May:316:110992. PMID: 41865607
Solvent & Solubility
H2O : 5 mg/mL (25.23 mM; Need ultrasonic)
DMSO : < 1 mg/mL (insoluble or slightly soluble)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: PBS
Solubility: 10 mg/mL (50.46 mM); Clear solution; Need ultrasonic and heat to 60°C
Purity & Documentation
-
Data Sheet (278 KB)
-
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Portuguese - PT (396 KB)
-
Handling Instructions (2659 KB)
References
[1]. Wei Wang, et al. Danshensu alleviates pseudo-typed SARS-CoV-2 induced mouse acute lung inflammation. Acta Pharmacol Sin. 2022 Apr;43(4):771-780. [Content Brief]
[2]. V Bharath Kumar, et al. Sodium Danshensu Inhibits Oral Cancer Cell Migration and Invasion by Modulating p38 Signaling Pathway. Front Endocrinol (Lausanne). 2020 Sep 30:11:568436. [Content Brief]
[3]. Chen Yu, et al. Danshensu attenuates cisplatin-induced nephrotoxicity through activation of Nrf2 pathway and inhibition of NF-κB. Biomed Pharmacother. 2021 Oct:142:111995. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O | 1 mM | 5.0462 mL | 25.2309 mL | 50.4617 mL | 126.1543 mL |
| 5 mM | 1.0092 mL | 5.0462 mL | 10.0923 mL | 25.2309 mL | |
| 10 mM | 0.5046 mL | 2.5231 mL | 5.0462 mL | 12.6154 mL | |
| 15 mM | 0.3364 mL | 1.6821 mL | 3.3641 mL | 8.4103 mL | |
| 20 mM | 0.2523 mL | 1.2615 mL | 2.5231 mL | 6.3077 mL | |
| 25 mM | 0.2018 mL | 1.0092 mL | 2.0185 mL | 5.0462 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Powered by Bioz